

Blue Cross Blue Shield of Vermont and The Vermont Health Plan
Prior Approval Guidelines
Ovidrel® (Choriogonadotropin alfa)
Non-IVF Fertility Uses

Description: An analog of Luteinizing hormone, this agent stimulates late follicular maturation and resumption of oocyte meiosis and initiates rupture of the pre-ovulatory ovarian follicle.

Covered Indications:

- 1) Ovulation induction is indicated in women whom the cause of anovulation is functional and not caused by primary ovarian failure.
- 2) Non-in vitro fertilization (IVF) fertility (Natural methods only)

Reasons for Prior Authorization:

<input checked="" type="checkbox"/> Cost	<input type="checkbox"/> Potential for misuse
<input type="checkbox"/> Toxicity	<input checked="" type="checkbox"/> Prevention of use for infertility- via in vitro fertilization

Criteria for Approval:

- 1) Diagnosis is an FDA-labeled indication **and**
- 2) Patient does not have any contraindications to use (see below)

Reasons for Denial of Benefit:

- 1) Patient does not meet Criteria for Approval
- 1) Patient has any of the following **contraindications**
 -) Pregnant or lactating
 -) Undiagnosed abnormal vaginal bleeding
 -) Primary ovarian failure
 -) Uncontrolled thyroid or adrenal function
 -) Ovarian cysts or enlargement not due to polycystic ovary syndrome
 -) Presence of any cause of infertility other than anovulation
 -) Prior hypersensitivity to human chorionic gonadotropin
 -) Uncontrolled organic intracranial lesion such as a pituitary tumor
 -) Sex hormone dependent tumors of the reproductive tract and accessory organs
- 3) Patient is planning pregnancy via in vitro fertilization
- 4) Patient has already had a trial of an ovulation induction medication in the last 12 months.

Benefit Approval:

- 1) Non-IVF pregnancy; 4-cycles per calendar year (4 months);
Limited to one ovulation induction medication per year.

Notes:

- 1) This medication will not be approved for purposes of IVF fertility

References:

1. Olin BR, ed. Drug Facts and Comparisons. Facts and Comparisons. St. Louis, 2004
2. Package insert, Ovidrel® Serono, Inc. Rockland, MA 2002